<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434574</url>
  </required_header>
  <id_info>
    <org_study_id>Aronia BP</org_study_id>
    <nct_id>NCT03434574</nct_id>
  </id_info>
  <brief_title>Aronia Berry Consumption on Blood Pressure</brief_title>
  <acronym>ABP</acronym>
  <official_title>Evaluation of the Effect of Chokeberry (Aronia Melanocarpa) Polyphenols on Blood Pressure in Prehypertensive Healthy Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naturex-Dbs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aronia berries are a native North American berry with high naturally occurring anthocyanins&#xD;
      among other polyphenols. Based on their polyphenol composition, there is growing interest in&#xD;
      the potential for Aronia berries to elicit health promoting cardio-metabolic effects.&#xD;
      Specifically, Aronia berry extracts, which provide a concentrated source of polyphenols, may&#xD;
      improve blood vessel function.&#xD;
&#xD;
      Thus, the primary focus of this project is to evaluate the effects of Aronia berry&#xD;
      polyphenols on blood pressure and other biomarkers of cardiovascular disease risk such as&#xD;
      endothelial function, arterial stiffness and blood lipids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline ambulatory blood pressure after 12-week consumption</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on ambulatory 24-hour systolic and diastolic blood pressure at 12 weeks post consumption, compared to the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office blood pressure</measure>
    <time_frame>Baseline 0 and 2 hours and 12 weeks 0 and 2 hours</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on office systolic and diastolic blood pressure, at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Baseline 0 and 2 hours and 12 weeks 0 and 2 hours</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on heart rate, at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>Baseline 0 and 2 hours and 12 weeks 0 and 2 hours</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on flow-mediated dilation at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood flow velocity</measure>
    <time_frame>Baseline 0 and 2 hours and 12 weeks 0 and 2 hours</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on blood flow velocity at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity (PWV)</measure>
    <time_frame>Baseline 0 and 2 hours and 12 weeks 0 and 2 hours</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on pulse wave velocity (PWV) using a Sphygmocor device, at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index (AIx)</measure>
    <time_frame>Baseline 0 and 2 hours and 12 weeks 0 and 2 hours</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on augmentation Index (AIx) using a Sphygmocor device, at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on blood lipids (Total, HDL and LDL cholesterol, triglycerides), at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cortisol</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on blood cortisol levels, at 12 weeks post consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of volunteers with treatment-related adverse events</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The number of volunteers with treatment-related adverse events will be assessed by questionnaires and interviews.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour heart rate</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Determine the effect of the Aronia extract vs Placebo on 24-hour heart rate, using a monitor, at 12 weeks post consumption</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma aronia berry (poly)phenol metabolites</measure>
    <time_frame>Baseline 0 and 2 hours and 12 weeks 0 and 2 hours</time_frame>
    <description>Measured by liquid chromotography- mass spectrometry (LC/MS) 0 and 2 hours postconsumption at day 1 (baseline) and after 12 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Microbiome analysis</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Stool sample collection (Omnigene gut collection kit)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Prehypertension</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aronia extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aronia extract</intervention_name>
    <description>Powdered extract obtained from aronia berries (Aronia melanocarpa).</description>
    <arm_group_label>Aronia extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women aged 40-70 years old&#xD;
&#xD;
          -  Blood pressure comprised between: SBP 120/139 mmHg or DBP 80/89 mmHg&#xD;
&#xD;
          -  Subjects are willing to maintain their normal eating/drinking habits and exercise&#xD;
             habits to avoid changes in body weight over the duration of the study&#xD;
&#xD;
          -  Are able to understand the nature of the study&#xD;
&#xD;
          -  Able and willing to give signed written informed consent&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Manifest cardiovascular disease including coronary artery disease, cerebrovascular&#xD;
             disease and peripheral artery disease&#xD;
&#xD;
          -  Grade 1 hypertensive or above, as defined as SBP superior or equal to 140 mmHg or DBP&#xD;
             superior or equal to 90 mmHg&#xD;
&#xD;
          -  Obese participants, defined as BMI superior or equal to 30&#xD;
&#xD;
          -  Diabetes mellitus and metabolic syndrome&#xD;
&#xD;
          -  Acute inflammation&#xD;
&#xD;
          -  Chronic and acute disease&#xD;
&#xD;
          -  Terminal renal failure and other kidney abnormalities&#xD;
&#xD;
          -  Malignancies&#xD;
&#xD;
          -  Abnormal heart rhythm&#xD;
&#xD;
          -  Allergies to berries or other significant food allergy.&#xD;
&#xD;
          -  Subjects who require treatment for hypertension at any time (e.g. statins, aspirin,&#xD;
             blood pressure lowering drugs)&#xD;
&#xD;
          -  Subjects who took food supplements, dietary supplement or herbal remedies within 1&#xD;
             month of study start&#xD;
&#xD;
          -  Subjects who have lost more than 10% of their weight in the past 6 months or are&#xD;
             currently in a diet&#xD;
&#xD;
          -  Subjects who reported participant in another study within 1 month before the study&#xD;
             start&#xD;
&#xD;
          -  Subjects who smoke an irregular amount of cigarettes per day&#xD;
&#xD;
          -  Subjects who require chronic antimicrobial or antiviral treatment&#xD;
&#xD;
          -  Subjects with unstable psychological condition&#xD;
&#xD;
          -  Subjects with history of cancer, myocardial infarction, cerebrovascular incident&#xD;
&#xD;
          -  Unable to swallow the capsule&#xD;
&#xD;
          -  Pregnant, lactating or planning to become pregnant, as well as premenopausal women who&#xD;
             do not have an adequate method of contraception&#xD;
&#xD;
          -  Any reason or condition that in the judgment of the clinical investigator(s) may put&#xD;
             the subject at unacceptable risk or that may preclude the subject from understanding&#xD;
             or complying with the study's requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Life Sciences and Medecine</name>
      <address>
        <city>London</city>
        <state>Central London</state>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Dr Ana Rodriguez-Mateos</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>(Poly)phenols</keyword>
  <keyword>Aronia berry</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Vascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

